Halozyme Therapeutics.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 53
What's happening
Earlier this month
Gone quiet
No new reports in 90+ days-
Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.Some support2 reports1 development inside
-
Halozyme tracks patient usage of OCREVUS ZUNOVO and monitors Opdivo Qvantig sales and conversion rates.Some support1 report
-
Halo, a biopharmaceutical company based in San Diego, and Leidos and TransUnion are mentioned as stocks for investment.Some support14 reports
-
Halozyme Therapeutics, listed on Nasdaq, received a buy rating from TD Cowen, which was disclosed to the SEC.Some support2 reports
-
Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.Well supported3 reports
-
CMS drug pricing guidance introduces uncertainty and regulatory changes affect royalty revenue growth for Halozyme Therapeutics.Some support2 reports
-
Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.Some support5 reports
-
Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.Some support4 reports
-
Janssen received EC approval for DARZALEX Faspro co-formulated with ENHANZE.Some support1 report
-
H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.Some support1 report
-
T. Rowe Price and Halozyme Therapeutics were highlighted as strong investment opportunities on September 3, 2025.Some support1 report
-
Halozyme Therapeutics' stock gain contrasts with the performance of the medical sector.Some support5 reports
No events began in the chosen period. Widen it, or reset.
Around Halozyme Therapeutics this week
News at the entities that move Halozyme Therapeutics most-
AbbVie StructuralAbbVie announced a joint development partnership with IGI, led by Lida Pacaud.Moves Halozyme Therapeutics
-
Hoffmann-La Roche StructuralMajor pharmaceutical companies licensed drug delivery technologies like Enhanze and Hypercon for various applications.Moves Halozyme Therapeutics
-
Bristol-Myers Squibb StructuralGardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.Moves Halozyme Therapeutics
-
Leerink partners Mentioned togetherLeerink Partners provided coverage and price targets for Freenome on September 26, 2026.Moves Halozyme Therapeutics
-
SEC StructuralDirector Arne Wilhelmsen sold shares of Royal Caribbean Cruises Ltd. and disclosed the transaction to the SEC.Moves Halozyme Therapeutics
-
Incyte OperationalAmgen, Vertex, and Incyte shares traded on Nasdaq, and Robert A. Bradway leads Amgen's long-term growth strategy.Moves Halozyme Therapeutics
Connections
The 21 strongest of 53, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
AbbVie Structural
AbbVie utilizes proprietary ENHANZE technology licensed from Halozyme Therapeutics.
-
Hoffmann-La Roche Structural
Roche utilizes Halozyme's ENHANZE drug delivery technology under a licensing agreement, generating royalty payments.
-
Bristol-Myers Squibb Structural
Halozyme licensed its drug delivery technology to Bristol-Myers Squibb, establishing an ongoing royalty and supply partnership.
-
Incyte Operational
The companies have established a global partnership to develop subcutaneous formulations of the drug candidate INCA033989.
-
Merck Operational
Halozyme and Merck are engaged in ongoing intellectual property litigation over MDASE patents.
-
Pfizer Transactional
Halozyme repeatedly licensed its ENHANZE technology to Pfizer.
-
Janssen Structural
Halozyme licenses its ENHANZE technology to Janssen, which uses it to co-formulate pharmaceutical products.
-
Nasdaq Structural
Halozyme Therapeutics is a publicly listed company on the Nasdaq exchange.
Show all 21 connections
-
Johnson & Johnson Structural
Johnson & Johnson is a formal partner in Halozyme's royalty portfolio and makes royalty payments for Darzalex.
-
Vertex Pharmaceuticals Structural
The relationship is characterized by a formal partnership structure where one entity operates as a subsidiary regarding Hypercon technology.
-
Morgan Stanley Mentioned together
Morgan Stanley provides financial analysis, including price targets and upgrades, on Halozyme Therapeutics.
-
Leerink partners Mentioned together
Leerink Partners functions as an analyst firm, providing market research reports and assessments on Halozyme Therapeutics.
-
SEC Structural
Halozyme Therapeutics is subject to formal oversight and disclosure requirements of the SEC.
-
Benchmark Mentioned together
Benchmark provides analyst coverage, including Buy ratings and stock monitoring, for Halozyme Therapeutics.
-
TD Cowen Transactional
TD Cowen provided and reaffirmed a buy rating on Halozyme Therapeutics shares.
-
NeoGenomics Mentioned together
Both NeoGenomics and Halozyme Therapeutics are listed as top holdings in a First Trust fund.
-
Corcept Therapeutics Mentioned together
Both companies are included in the same First Trust investment fund.
-
Belgium Shared context
Halozyme Therapeutics operates within the geographical context of Belgium.
-
San Diego Shared context
Halozyme Therapeutics is headquartered and based in San Diego, California.
-
Biotech Mentioned together
Halozyme Therapeutics is classified as a biopharma technology platform company, placing it within the broader biotech sector.
-
Citigroup Mentioned together
No evidence was found in the timeline linking Citigroup and Halozyme Therapeutics.
History
Events by the month they beganOctober 2026
2 eventsAugust 2026
1 eventJune 2026
11 events- Royalty payments from Roche and J&J for various drugs, alongside Argenx's demand and the acquisition of Antares Pharma's Xyosted, were reported.
- Halo, a biopharmaceutical company based in San Diego, and Leidos and TransUnion are mentioned as stocks for investment.
- Halozyme Therapeutics, listed on Nasdaq, received a buy rating from TD Cowen, which was disclosed to the SEC.
- Halozyme Therapeutics received European regulatory approval, while Morgan Stanley upgraded its stock and it filed a patent lawsuit against Merck Sharp & Dohme.
- CMS drug pricing guidance introduces uncertainty and regulatory changes affect royalty revenue growth for Halozyme Therapeutics.
- Halozyme Therapeutics' ENHANZE technology is being utilized by major pharmaceutical companies including AbbVie, Roche, and Lilly.
- Morgan Stanley raised price targets on Halozyme Therapeutics, noting the company may benefit from Trump-era tariffs.
- Janssen received EC approval for DARZALEX Faspro co-formulated with ENHANZE.
- H.C. Wainwright analysts raised the price target for Halozyme Therapeutics on August 12, 2025.
- T. Rowe Price and Halozyme Therapeutics were highlighted as strong investment opportunities on September 3, 2025.
- Halozyme Therapeutics' stock gain contrasts with the performance of the medical sector.